NCT02495168: A trial that was reported late by Actavis Inc.
This trial has reported, although it was 118 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT02495168 |
|---|---|
| Title | A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter, Multinational Study to Compare the Therapeutic Equivalence of a Budesonide 80 μg/Formoterol Fumarate Dihydrate 4.5 μg Inhalation Aerosol (Manufactured by Catalent for Watson Laboratories Inc.) to Symbicort® (Budesonide 80 μg/Formoterol Fumarate Dihydrate 4.5 μg Inhalation Aerosol) (Manufactured by AstraZeneca) in Adolescent and Adult Patients With Asthma |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Jan. 13, 2017 |
| Completion date | May 31, 2018 |
| Required reporting date | May 31, 2019, midnight |
| Actual reporting date | Sept. 26, 2019 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 118 |